INDEX

A
Acid(s), weak, acid-base disorders and, 560
Acid-base abnormalities
fluid therapy in vomiting and diarrhea for, 663
vomiting and diarrhea and, 658
Acid-base analysis, blood gas results and, 543–544
Acid-base derangements, management of, 738–739
Acid-base disorders
hypoalbuminemic alkalosis and, 562
hypocholemic alkalosis and, 562
metabolic, in CCU, 559–574
metabolic acidosis and, 562–571. See also Metabolic acidosis, causes of.
metabolic alkalosis and, 561–562
strong ions and, 560
weak acids and, 560
Acid-base imbalance
diabetes mellitus and, 700–701
fluid therapy complications related to, 610
Acidemia, blood gas results and, 546
Acidosis
hyperchloremic, metabolic acidosis due to, 565
hyperphosphatemic, metabolic acidosis due to, 564–565
hypoalbuminemic, acid-base disorders and, 562
in glucocorticoid deficiency
management, 713
lactic, metabolic acidosis due to, 568–571
metabolic. See Metabolic acidosis.
respiratory. See Respiratory acidosis.
Azotemia, management of, 730–735

Acute respiratory distress syndrome (ARDS), fluid therapy in patients with, 722–723
Adolescent(s), fluid therapy in, 626–627
Albumin
described, 595–598
fluid therapy complications related to, 613–614
in critically ill dogs and cats, 595–605
costs of, 598
indications for, 599
25% human serum, in critically ill dogs and cats, 600–602
administration of, 601
adverse effects of, 601–602
delayed immune-mediated reactions due to, treatment for, 602–603
Alkalemia, blood gas results and, 546
Alkalosis
hypochloremic, acid-base disorders and, 562
metabolic. See Metabolic alkalosis.
respiratory. See Respiratory alkalosis.
Alveolar gas equation, 423
Alveolar-arterial oxygen difference, 424
Anion gap
analysis of, 444–446
changes in, causes of, 445, 447
described, 443
quick reference for, 443–447
ARDS. See Acute respiratory distress syndrome (ARDS).
Azotemia, management of, 730–735

B
Bicarbonate, for DKA or HHS in diabetes mellitus, 705
Blood gas analysis
clinical examples of, 553–556
results of acid-base vs. respiratory function and, 543–544
acidemia and, 546

Note: Page numbers of article titles are in boldface type.
Blood gas (continued)
alkalemia and, 546
base excess, 548–549
compensated, 547–548
making sense of, 543–557
nonrespiratory disturbances and, causes of, 549–551
physiology and, 545–546
respiratory, assessment of, 551–553
respiratory vs. nonrespiratory, 546–547
sampling methods in, 544–545
Blood pressure, in global tissue perfusion assessment, 630
Blood products
fluid therapy complications related to, 615–616
in vomiting and diarrhea, 659
Body fluids, physiology of, 575–576

C
Calcium, 499–504
abnormalities of, in renal failure, 692–693
ionized, measurement of, 501–502
total
adjusted, 500–501
measurement of, 499–500
Canine parvoviral enteritis, vomiting and diarrhea related to, management of, fluid therapy in, 670–673
Cardiogenic shock, described, 632
Cat(s), critically ill, albumin in, 595–605.
See also Albumin.
Catheterization, intravenous, fluid therapy complications related to, 607–609
CCU. See Critical care unit (CCU).
Children, fluid therapy in, 621–627. See also Fluid therapy, in children.
Chloride
abnormalities of, in renal failure, 688–689
analysis of, 459–461
quick reference for, 459–465
urine sodium and, 504–507
Colloid(s), 587–593
guidelines for use of, 588–590
in vomiting and diarrhea, 659
new synthetic, development of, 590–591
Colloid fluids, fluid therapy complications of, 614–615
Contusion(s), pulmonary, fluid therapy in patients with, 721–722
Critical care unit (CCU), metabolic acid-base disorders in, 559–574
Crystalloid(s), in vomiting and diarrhea, 659
Crystalloid fluids, complications of, 609
D
Dehydration, vomiting and diarrhea and, 655–656
fluid therapy for, 661–662
Demyelination, osmotic, in glucocorticoid deficiency management, 714–715
Diabetes mellitus
acid-base imbalance in, 700–701
complications of, 700–702
described, 699
diabetic ketoacidosis in, 699–707
fluid and electrolyte imbalances in, 701–702
fluid and electrolyte therapy in, 699–717
HHS and, 699–707
pathophysiology of, 699–700
treatment of, 702–707
bicarbonate in, 705
fluids in, 702–704
insulin in, 706–707
phosphorus in, 705–706
potassium in, 704–705
Diabetic ketoacidosis
diabetes mellitus and, 699–707
metabolic acidosis due to, 567–568
Diarrhea
acid-base disturbances due to, 658
consequences of, 655–658
dehydration due to, 655–656
electrolyte disorders due to, 657–658
fluid therapy in, 653–675. See also Fluid therapy, in vomiting and diarrhea.
hypovolemia due to, 656–657
mechanisms of, 654–655
Distributive shock, described, 632
Dog(s), critically ill, albumin in, 595–605.
See also Albumin.
Drug(s), for fluid and electrolyte balance in heart failure, 741–742
E
Electrolyte(s)
abnormalities of, fluid therapy in vomiting and diarrhea for, 663
emergencies related to, therapeutic approach to, 513–533. See also specific modalities, e.g.,
Hyperkalemia
hypercalcaemia, 525–528
hyperkalemia, 515–518
hyponatremia, 522–524
hypocalcemia, 524–525
hypokalemia, 513–515
hyponatremia, 518–522
in management of fluid and electrolyte disorders in renal failure, 688–693
urinary, 503–512

Electrolyte disorders
chronic, therapeutic approach to, 535–541
magnesium, 539–540
potassium, 537–539
sodium, 535–537
vomiting and diarrhea and, 657–658

Electrolyte imbalances, fluid therapy complications related to, 610

Electrolyte therapy, 699–717
Endocrine disorders, fluid and electrolyte therapy in, 699–717
Enteritis, parvoviral, canine, vomiting and diarrhea related to, fluid therapy for, 670–673

Fluid(s)
body, physiology of, 575–576
colloid, complications of, 614–615
crystalloid, complications of, 609
in neonates, 621–626. See also Fluid therapy, in neonates.
types of, 576–579

Fluid and electrolyte balance, in heart failure azotemia, 730–735
maintenance of, 727–745
management of, 727–745
potassium derangements, 736–737

Fluid and electrolyte disorders, in renal failure, management of fluid therapy in, 677–697
converting oliguria to nonoliguria, 683–686
discontinuation of, 687
electrolyte abnormalities related to, 688–694
hydration assessment in, 678–679
monitoring during, 686–687
nutritional support, 688
outpatient, 687–688
route of administration, 679
type of fluid, 679–681
volume and rate, 681–683
metabolic acidosis due to, 694–695

Fluid and electrolyte therapy, in endocrine disorders, 699–717

Fluid dynamics, in lungs, overview of, 719–720

Fluid resuscitation, in trauma patients, 645–652. See also Trauma patients.

Fluid therapy administration of
procedure for, 580–582
rational, 575–586
complications of, 607–619
acid-base imbalances, 610
albumin-related, 613–614
blood products–related, 615–616
colloid fluids–related, 614–615
correction of hypernatremia and, 610–611
crystallloid fluids and, 609
electrolyte imbalances, 610
hemoglobin-based oxygen carriers, 615
hypokalemia, 611
intravenous catheterization and, 607–609
intravenous volume overload, 611–613
parenteral nutrition products–related, 616–617
contraindications to, 584
discontinuation of, 584–585
fluids for, types of, 576–579
for DKA or HHS in diabetes mellitus, 702–704
for fluid and electrolyte disorders in renal failure, 677–697. See also Fluid and electrolyte disorders, in renal failure, management of, fluid therapy in.
for hypovolemic states, 633–638
for patients in renal failure, 678
in adolescents, 626–627
in children, 621–627. See also Adolescent(s), fluid therapy in; Infant(s), fluid therapy in; Neonate(s), fluid therapy in.
in glucocorticoid deficiency management, 710–711
in infants, 626
in neonates, 621–626
described, 621–622
intraosseous fluids, 625
intravenous fluids, 624
isoelectrolysis, 625–626
oral fluids, 622–623
subcutaneous fluids, 623–624
in patients with pulmonary disease, 719–725
acute lung injury, 722–723
ARDS, 722–723
described, 721
pulmonary contusions, 721–722
in vomiting and diarrhea, 653–675
blood products, 659
colloids, 659
Fluid therapy (continued)
- crystalloids, 659
- for acid-base abnormalities, 663
- for canine paroviral enteritis, 670–673
- for dehydration, 661–662
- for electrolyte abnormalities, 663
- for gastrointestinal obstruction, 665–667
- for hypoadrenocorticism, 667–670
- for hypovolemia, 662–663
- indications for, 661–664
- nutritional support in, 664
- oncotic support in, 664
- route of administration of, 659–661
- types, 658–661
- monitoring of, 582–584
- options for, 575–586
- reasons for, 579–580

G
- Gastrointestinal obstruction, vomiting and diarrhea related to, management of, fluid therapy in, 665–667
- Glucocorticoid(s), in glucocorticoid deficiency management, 713–714
- Glucocorticoid deficiency, 709–715
  - described, 709–710
  - treatment of, 710–715
  - acidosis in, 713
  - fluids in, 710–711
  - glucocorticoids in, 713–714
  - hyperkalemia in, 711–713
  - maintenance therapy in, 715
  - osmotic demyelination in, 714–715
- Glucose derangements, management of, 739

H
- Heart failure
  - fluid accumulation in, management of, 728–730
  - fluid and electrolyte balance in, maintenance of, 727–745. See also Fluid and electrolyte balance, in heart failure, maintenance of.
- Hemoglobin-based oxygen carriers, fluid therapy complications related to, 615
- HHS. See Hyperglycemic hyperosmolar syndrome (HHS).
- Hydration, assessment of, in fluid and electrolyte disorders in renal failure, 678–679
- Hypercalcemia, 525–528
  - analysis of, 449–452
  - causes of, 450–453, 525–526
  - clinical signs of, 453, 526
  - defined, 525
  - diagnosis of, 526
  - quick reference for, 449–453
  - treatment of, 526–528
  - stepwise approach in, 453
- Hypercholesterolemia, corrected, 462–464
- Hyperchloremic acidosis, metabolic acidosis due to, 565
- Hyperglycemic hyperosmolar syndrome (HHS), diabetes mellitus and, 699–707
- Hyperkalemia, 515–518
  - analysis of, 477–480
  - causes of, 478, 480, 515–516
  - clinical findings in, 516
  - clinical signs of, 480
  - described, 515
  - in glucocorticoid deficiency management, 711–713
  - in renal failure, 690–692
  - quick reference for, 477–480
  - treatment of, 516–518, 537–538
  - stepwise approach in, 480
- Hypermagnesemia, therapeutic approach to, 539–540
- Hypernatremia, 522–524
  - analysis of, 485–486
  - causes of, 486–487, 522
  - clinical signs of, 486–487, 523
  - correction of, fluid therapy complications related to, 610–611
  - described, 522
  - differential diagnosis of, 523
  - pathophysiology of, 522–523
  - quick reference for, 485–489
  - treatment of, 523–524, 535–537
  - stepwise approach in, 487–488
- Hyperphosphatemia, 473–475
- Hyperphosphatemic acidosis, metabolic acidosis due to, 564–565
- Hypoadrenocorticism
  - causes of, 707
  - described, 707
  - diagnosis of, 707–708
  - fluid and electrolyte therapy in, 699–717
  - glucocorticoid deficiency, 709–715.
    - See also Glucocorticoid deficiency.
  - mineralocorticoid deficiency and, 708–709
  - vomiting and diarrhea related to, management of, fluid therapy in, 667–670
- Hypoalbuminemic alkalosis, acid-base disorders and, 562
- Hypocalcemia, 524–525
  - analysis of, 455–457
causes of, 456–458, 524
clinical signs of, 458, 524
defined, 524
diagnosis of, 524–525
pathophysiology of, 524
quick reference for, 455–458
treatment of, 525
stepwise approach in, 458
Hypochloremia, corrected, 461–462
Hypochloremic alkalosis, acid-base disorders and, 562
Hypokalemia
analysis of, 481–483
causes of, 482, 484, 513
clinical findings in, 513–514
clinical signs of, 484
described, 513
fluid therapy complications related to, 611
in renal failure, 689–690
quick reference for, 481–484
treatment of, 514–515, 538–539
stepwise approach in, 484
Hypomagnesemia, therapeutic approach to, 539–540
Hyponatremia, 518–522
analysis of, 491–492
causes of, 492–495, 518–519
clinical findings in, 520
clinical signs of, 495
extracellular volume in
high, 521
low, 520–521
normal, 521
pathophysiology of, 519–520
quick reference for, 491–495
sodium replacement rate in, calculation of, 521–522
treatment of, 520, 537
stepwise approach in, 495
Hypophosphatemia, 472–473
Hypovolemia
classification of, 631–632
defined, 629
emergency therapy for, requirements for, 633
fluid therapy in vomiting and diarrhea for, 662–663
treatment of, 632–633
fluid therapy in
route of administration of, 633–638
types, 633–638
vomiting and diarrhea and, 656–657
Hypovolemic shock, described, 632
Hypovolemic states, 629–643
treatment of
ancillary therapies in, 639–640
resuscitation in, goals and end points of, 638
Hypoxemia
analysis of, 424
clinical approach to, 424–426
quick reference for, 423–426
Infant(s), fluid therapy in, 626
Insulin, for DKA or HHS in diabetes mellitus, 706–707
Intraosseous fluids, in neonates, 625
Intrapertoneal fluids, in neonates, 624
Intravenous catheterization, fluid therapy complications related to, 607–609
Intravenous fluids, in neonates, 624
Intravenous volume overload, fluid therapy complications related to, 611–613
Ion(s), strong, acid-base disorders and, 560
Ion gap, strong, quick reference for, 443–447.
See also Strong ion gap.
Isoerythrolysis, neonatal, 625–626
Ketoacidosis, diabetic
diabetes mellitus and, 699–707
metabolic acidosis due to, 567–568
Lactic acidosis, metabolic acidosis due to, 568–571
Lung(s), fluid dynamics in, overview of, 719–720
Magnesium
abnormalities of, in renal failure, 693
deficit of
causes of, 467–469
diagnosis of, 469
manifestations of, 467–469
distribution of, 467
electrolyte disorders related to, 539–540
handling of, 467
quick reference for, 467–470
supplementation of, 470
Magnesium derangements, management of, 737–738
Metabolic acid-base disorders, in CCU, 559–574
Metabolic acidosis
acid-base disorders and, 562–571
analysis of, 439–441
causes of, 441, 562–571
diabetic ketoacidosis, 567–568
hyperchloremic acidosis, 565
hyperphosphatemic acidosis,
564–565
lactic acidosis, 568–571
toxin-induced acidosis, 566–567
uremic acidosis, 565–566
clinical signs of, 442
management of fluid and electrolyte
disorders in renal failure and,
694–695
quick reference for, 439–442
Metabolic alkalosis
acid-base disorders and, 561–562
analysis of, 435
causes of, 436–438
clinical signs of, 438
quick reference for, 435–438
Metabolic derangements, management of,
730–741
acid-base derangements, 738–739
glucose derangements, 739
magnesium derangements, 737–738
plasma protein derangements, 739–741
red blood cell derangements, 739–741
sodium derangements, 735–736
Mineralocorticoid deficiency, 708–709

Neonate(s)
fluid therapy in, 621–626. See also Fluid
therapy, in neonates.
sick, initial assessment of, 622
Nonoliguria, oliguria to, in management of
fluid and electrolyte disorders in renal
failure, 683–686
Nutritional support
in fluid and electrolyte disorders in renal
failure, 688
in fluid therapy in vomiting and
diarrhea, 664

Obstructive shock, described, 632
Oliguria, to nonoliguria, in management of
fluid and electrolyte disorders in renal
failure, 683–686
Oncotic support, in fluid therapy in vomiting
and diarrhea, 663–664
Ontario Veterinary College Veterinary
Teaching Hospital (OVC-VTH), 599
Oral fluids, in neonates, 622–623
Osmolality, 507–509
Osmotic demyelination, in glucocorticoid
deficiency management, 714–715
OVC-VTH. See Ontario Veterinary College
Veterinary Teaching Hospital (OVC-VTH).
Oxygen carriers, hemoglobin-based, fluid
therapy complications related to, 615

Parenteral nutrition products, fluid therapy
complications related to, 616–617
Parvoviral enteritis, canine, vomiting and
diarrhea related to, management of,
fluid therapy in, 670–673
Phosphorus
abnormalities of, in renal failure,
693–694
analysis of, 472
for DKA or HHS in diabetes mellitus,
705–706
functions of, 471
quick reference for, 471–475
Plasma, species-specific, in critically ill dogs
and cats, 599–600
Plasma protein derangements, management
of, 739–741
Potassium
electrolyte disorders related to, 537–539
for DKA or HHS in diabetes mellitus,
704–705
Potassium abnormalities, in renal failure,
689–692
Potassium derangements, management of,
736–737
Proteinuria, 510
Pulmonary contusions, fluid therapy in
patients with, 721–722
Pulmonary disease, fluid therapy in patients
with, 719–725. See also Fluid therapy, in
patients with pulmonary disease.

Red blood cell derangements, management
of, 739–741
Renal failure
fluid and electrolyte disorders in,
management of, 677–697. See also Fluid
and electrolyte disorders, in renal
failure, management of.
fluid therapy in, 678
for hospitalized patients, 678
Respiratory acidosis
analysis of, 431–432
causes of, 432–433
quick reference for, 431–434
signs of, 433
stepwise approach to, 433–434
Respiratory alkalosis
analysis of, 427–428
causes of, 427–429
quick reference for, 427–430
signs of, 430
stepwise approach to, 430
Respiratory function, assessment of, blood gas results and, 551–553

S
Shock
cardiogenic, described, 632
classification of, 631–632
consequences of, 629
defined, 629
distributive, described, 632
hypovolemic, described, 632
obstructive, described, 632
Sodium, electrolyte disorders related to, 535–537
Sodium abnormalities, in renal failure, 688–689
Sodium derangements, management of, 735–736
Solute(s), 503–512
Species-specific plasma, in critically ill dogs and cats, 599–600
Strong ion(s), acid-base disorders and, 560
Strong ion gap
analysis of, 444–446
changes in, causes of, 445, 447
described, 443–444
quick reference for, 443–447
Subcutaneous fluids, in neonates, 623–624

T
Tissue perfusion
downstream parameters in, 630–631
global, assessment of, blood pressure in, 630
status of, clinical assessment of, 629
Toxin-induced acidosis, metabolic acidosis due to, 566–567
Trauma, pathophysiology of, 645–647
Trauma patients
assessment of, 647
fluid resuscitation in, 645–652
monitoring of, 650–651
resuscitation of, 647–650
25% human serum albumin, in critically ill dogs and cats, 600–602. See also Albumin, human serum, in critically ill dogs and cats.

U
Uremic acidosis, metabolic acidosis due to, 565–566
Urinary electrolytes, 503–512
Urine, indices of, 509–510
Urine sodium, chloride and, 504–507
Urine solute, measurements of, 504

V
Vomiting
acid-base disturbances due to, 658
consequences of, 655–658
dehydration due to, 655–656
electrolyte disorders due to, 657–658
fluid therapy in, 653–675. See also Fluid therapy, in vomiting and diarrhea.
hypovolemia due to, 656–657
mechanisms of, 653–654